Mark J. Foley Sells 10,000 Shares of Zeltiq Aesthetics Inc. (ZLTQ) Stock
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) insider Mark J. Foley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 13th. The stock was sold at an average price of $40.55, for a total transaction of $405,500.00. Following the sale, the insider now directly owns 281,941 shares of the company’s stock, valued at approximately $11,432,707.55. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) opened at 38.90 on Tuesday. The company has a market capitalization of $1.54 billion, a PE ratio of 58.50 and a beta of 0.79. The firm’s 50-day moving average price is $39.24 and its 200 day moving average price is $32.56. Zeltiq Aesthetics Inc. has a 52 week low of $18.41 and a 52 week high of $41.48.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.07. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The company earned $89.50 million during the quarter, compared to the consensus estimate of $79.68 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts expect that Zeltiq Aesthetics Inc. will post ($0.13) earnings per share for the current fiscal year.
Several analysts have recently commented on ZLTQ shares. Zacks Investment Research raised shares of Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research report on Saturday, July 23rd. Leerink Swann reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a research report on Thursday, June 30th. Brean Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Zeltiq Aesthetics in a research report on Tuesday, June 21st. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a research report on Tuesday, August 9th. Finally, Stifel Nicolaus raised their price objective on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, September 21st. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $39.89.
A number of hedge funds have recently made changes to their positions in the stock. PineBridge Investments L.P. increased its stake in shares of Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock valued at $112,000 after buying an additional 193 shares during the last quarter. Teacher Retirement System of Texas increased its stake in shares of Zeltiq Aesthetics by 26.9% in the second quarter. Teacher Retirement System of Texas now owns 4,884 shares of the company’s stock valued at $133,000 after buying an additional 1,036 shares during the last quarter. First Mercantile Trust Co. bought a new stake in shares of Zeltiq Aesthetics during the third quarter valued at $204,000. Riverhead Capital Management LLC increased its stake in shares of Zeltiq Aesthetics by 492.3% in the second quarter. Riverhead Capital Management LLC now owns 5,775 shares of the company’s stock valued at $289,000 after buying an additional 4,800 shares during the last quarter. Finally, Mason Street Advisors LLC bought a new stake in shares of Zeltiq Aesthetics during the second quarter valued at $173,000.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.